BRH Braveheart Investment Group Plc

TIDMBRH

Braveheart Investment Group plc

02 June 2020

RNS Reach announcement (non-regulatory)

2 June 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Operational update on Kirkstall Limited

Braveheart (AIM: BRH), the fund management and strategic investment group, is pleased to provide an operational update on its strategic investment Kirkstall Limited.

Kirkstall Limited ("Kirkstall") (holding 80%)

Further to the announcement on 23 April 2020, which reported that Kirkstall is now collaborating with Animal Free Research UK, the UK's leading non-animal medical research charity, awarding grants to research scientists to implement new and existing techniques to replace the use of animal in trials and research.

Animal Free Research UK's assessment panel has awarded the first three projects that will use Kirkstall's Quasi Vivo(R) system in research related to COVID-19:

   1.   Dr Carolina Herrera, Imperial College London 

Project Title : Modelling early immune responses to SARS-CoV-2 in a fluidic system

Dr Herrera's Project Description : "To develop a model that mimics infection of SARS-CoV-2 taking into consideration the natural flow of lymph and blood in the body. With this model we want to assess the cellular responses to the entry of SARS-CoV-2 in cells from the respiratory tract and the effect of such responses on circulating blood cells from the immune system. We will be able to isolate the responses triggered by viral entry using a virus that cannot replicate in the infected cell. We will also test drug candidates for their potential to inhibit the first steps of infection and therefore the first stage of the inflammation process.

"The Kirkstall system allows us to measure the number of infected cells and their responses to the infection; and at the same time to observe the consequences of the infection on blood cells that are circulating, mimicking what happens in the human body."

   2.   Dr Mark Turner, Centre for Sport, Exercise and Life Sciences, Coventry University 

Project Title: A human-relevant system to investigate obesity, diabetes and COVID-19.

Dr Turner's Project Description: "Obesity and type 2 diabetes impacts the function of several organs in the body which can result in the development of other diseases but also increase the susceptibility of viral infections. It has been shown that obesity is a risk factor for developing severe symptoms from SARS-COVID-19 and therefore understanding why this is the case is highly important for scientists and doctors.

Several animal models have been used to investigate obesity, however making comparisons is difficult due to the differences between animals and human metabolism. Therefore, developing a system which replaces animal use and accurately replicates human obesity can address this issue. This project aims to establish a multi tissues model in the Quasi Vivo system which replicates human obesity which can be used to understand how different tissues behave and communicate with each other as well as the influence of diseases like SARS-COVID-19 in obesity."

   3.   Dr Baishakhi Ghosh, Johns Hopkins Bloomberg School of Public Health 
   Project Title:   Susceptibility of COPD and cigarette smoke airway epithelia to SARS-CoV-2. 

Dr Ghosh's Project Description: " The lungs are the organs most affected by COVID-19 as the SARS-CoV-2 virus results in asymptomatic or mild symptoms hospitalizations and mortality due to respiratory failure. Given the enormous impact of the virus on health and well-being, it is important to get insight into its pathogenic interaction with humans. We are exploring the epithelial changes that lead to increased susceptibility to disease, and also, quantifying changes that occur after viral exposure to determine the likelihood of chronic respiratory disease even after recovery from acute infection. Our understanding of the role of environmental exposures such as cigarette-smoke or vaping electronic cigarettes in modifying the response to SARS-CoV-2 is emerging and smoking has been associated with worsened outcomes in SARS-CoV-2 patients. The study will improve our understanding of how cigarette smoke increases our susceptibility to SARS-CoV-2 infection in the lungs and help in developing a therapy for prevention and treatment."

Carla Owen, CEO of Animal Free Research UK, said: "We are delighted to partner with Kirkstall Ltd to provide cutting-edge human relevant technology to scientists at three leading research institutes - Imperial College London, Johns Hopkins Bloomberg School of Public Health, and Coventry University - in efforts to understand COVID-19 as it affects humans. Deployment of the Quasi Vivo(R) system will contribute to the development of novel strategies for the prevention and treatment of SARS-CoV-2 infection."

For further information:

 
 Braveheart Investment Group plc          Tel: 01738 587555 
  Trevor Brown, Chief Executive Officer 
 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAEASKFEDDEEFA

(END) Dow Jones Newswires

June 02, 2020 02:00 ET (06:00 GMT)

Braveheart Investment (LSE:BRH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Braveheart Investment (LSE:BRH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024